Recurrent Female Reproductive System Carcinoma
2 clinical trials · Condition
◉ Watch Recurrent Female Reproductive System Carcinoma
| Record | Firm | Date |
|---|---|---|
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (NCT06483048) | Mayo Clinic | 2024-09-20 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
Track Recurrent Female Reproductive System Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.